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SLC transporters as therapeutic
targets: emerging opportunities
Lawrence Lin1, Sook Wah Yee1, Richard B. Kim2 and Kathleen M. Giacomini1,3

Abstract | Solute carrier (SLC) transporters — a family of more than 300 membrane-bound
proteins that facilitate the transport of a wide array of substrates across biological
membranes — have important roles in physiological processes ranging from the cellular
uptake of nutrients to the absorption of drugs and other xenobiotics. Several classes of
marketed drugs target well-known SLC transporters, such as neurotransmitter transporters,
and human genetic studies have provided powerful insight into the roles of more-recently
characterized SLC transporters in both rare and common diseases, indicating a wealth of
new therapeutic opportunities. This Review summarizes knowledge on the roles of SLC
transporters in human disease, describes strategies to target such transporters, and
highlights current and investigational drugs that modulate SLC transporters, as well as
promising drug targets.
Mendelian diseases
Disorders that are caused by
mutations in a single gene and
follow Mendelian inheritance
patterns.
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Transporters are membrane-bound proteins that mediate
the translocation of substrates across biological membranes. Membrane transporters are widely expressed
throughout the body, most notably in the epithelia of
major organs, such as the liver, intestine, kidney, and
organs with barrier functions, such as the brain, testes
and placenta. Different transporters are localized to the
plasma membrane, as well as to membranes that compose various subcellular organelles, thus ensuring the
regulated delivery of required substrates and thereby cell
ular homeostasis. Many transporters are also expressed
in an organ-specific manner, and facilitate the entry and
elimination of endogenous and xenobiotic compounds.
The two main transporter superfamilies are the ATPbinding cassette (ABC) superfamily and the solute carrier (SLC) superfamily. ABC transporters harness energy
from ATP hydrolysis and function as efflux transporters,
whereas SLC transporters are primarily involved in the
uptake of small molecules into cells. In drug development, there is considerable interest in transporters from
both families, particularly those with broad substrate
specificities — such as multidrug resistance protein 1
(MDR1; also known as P‑glycoprotein or ABCB1) and
organic anion transporter 1 (OAT1; also known as
SLC22A6) — and those that serve in the absorption, distribution and elimination of structurally and pharmacologically diverse drugs1. Such transporters may be the site
of drug–drug interactions that underlie drug toxicities.
By contrast, much less attention has been given by
drug developers to transporters with narrow substrate

specificities that function principally in the disposition
of endogenous compounds. However, defects in functionally specific transporters with narrow substrate
specificities have been linked to many Mendelian diseases
(also known as monogenic disorders). Monogenic dis
orders constitute a substantial source of novel drug
targets2 (given that the mutated-gene product is causal
for the disease), and moreover may provide important
insight into therapeutic opportunities for common diseases (BOX 1). Indeed, more than 80 SLC transporters
have been implicated in monogenic disorders, indicating
that this transporter superfamily could have substantial
untapped therapeutic potential.
In this article, we review the role of SLC transporters in
human health and discuss how defects in SLC transporters cause rare, monogenic disorders. We provide a brief
description of results from genome-wide association studies
(GWASs) that implicate SLC transporters in common disease, followed by a discussion of methodologies that may
be used to develop drugs to treat diseases associated with
genetic variants of SLC transporters. Finally, we highlight
examples of marketed drugs and candidates in clinical
development that target SLC transporters and discuss
future opportunities to target additional SLC transporters.

SLC transporters in health
Hydrophilic compounds, including charged molecules,
cannot readily diffuse across membranes and thus rely
on channels, pumps or transporters to move in and out
of cells and subcellular organelles. In humans, there
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Box 1 | Monogenic diseases as a source of drug targets
More than 7,000 monogenic diseases are described in the Online Mendelian
Inheritance in Man (OMIM) database (see Databases). Of these, the genes and the
primary mutations that underlie approximately 3,600 monogenic diseases have been
identified through candidate gene studies and linkage mapping within families155.
Monogenic disorders of known causes constitute a valuable source for the discovery
of novel drug targets in several ways2.
First, they provide the cause of the disease, which may provide a rationale for the
development of a new therapy. In particular, the mechanism of several drugs that are
approved to treat common diseases could have been rationalized through understanding
the causes of a Mendelian disease. For example, the mechanism responsible for the
beneficial effects of oestrogen-replacement therapy in osteoporosis can be rationalized
by knowing that mutations in the gene encoding the oestrogen receptor are associated
with osteoporosis in Mendelian disease156,157. Mutations in the gene encoding the
low-density lipoprotein (LDL) receptor that are associated with familial hypercholesterolaemia provide a rationale for the pharmacological effects of statins, which, through
interactions with their target, 3‑hydroxy‑3‑methyl-glutaryl-CoA (HMG-CoA) reductase,
result in upregulation of the LDL receptor and lower lipid levels158,159.
Second, monogenic disorders directly provide targets to treat disease; that is,
a mutated (loss‑of‑function) transporter that is causal for human disease is in itself a
drug target for that disease. In this case, high-throughput screening strategies can be
used to identify compounds that may enhance transport activity (such as potentiators)
or that enhance trafficking to the plasma membrane (such as correctors).
Furthermore, methods to bypass the transporter can be developed. Clinical findings
in patients with Amish lethal microcephaly (OMIM #607196) suggested a defect in
2‑ketoglutarate metabolism160 and SLC25A19 (which encodes the mitochondrial
deoxynucleotide carrier (DNC)) was identified as the gene responsible for this
disorder161. Studies in Slc25a19‑knockout mice revealed that DNC transports thiamine
pyrophosphate (TPP), which is a cofactor for enzymes involved in the citric acid
cycle, into the mitochondria162. The lack of TPP therefore explains the biochemical
characteristics of Amish lethal microcephaly. For treatment, the transporter can be
targeted with drugs to enhance its activity, or a method to bypass the transporter
can be developed — for example, delivery of TPP to the mitochondria.
Finally, a monogenic disorder may also suggest a target to treat a common disease.
For example, mutations in SLC5A2 that lead to hypoglycaemia in patients with familial
renal glucosuria (OMIM #233100), informed the development of sodium–glucose
cotransporter 2 (SGLT2) inhibitors for the treatment of hyperglycaemia associated
with type 2 diabetes.
Developing drugs to treat a rare disorder (known as orphan drugs) may pose greater
logistical and economical challenges than developing drugs to treat common diseases,
but the European Union and the United States incentivize the development of orphan
drugs by providing tax credits, waived user fees and enhanced patent protection to the
sponsor, resulting in considerable fiscal savings. In addition, there may be opportunities
to expand the use (and thus the market) of a drug developed for a rare indication to
other indications after its initial approval. For example, imatinib, which was initially
approved to treat chronic myelogenous leukaemia, was then rapidly approved for five
other indications, and now ranks in the top 25 pharmaceutical products globally,
making ~US$4.75 billion in worldwide sales in 2014 (see PMLive Top Pharma List in
Further information). Increasingly, there are pharmaceutical companies whose main
focus is to develop drugs for rare diseases, such as Alexion Pharmaceuticals, Ultragenyx
Pharmaceutical and Rare Disease Therapeutics, and many larger companies also have
units dedicated to rare diseases.

Genome-wide association
studies
(GWASs). Studies of multiple
genetic variants across the
genome in many individuals,
looking for association with a
given trait. In most GWASs,
more than 500,000 genetic
variants across the genome are
examined for association with a
certain trait of some individuals
that does not appear in others.

are 395 membrane-spanning SLC transporters that are
organized into 52 families. SLC transporters interact
with a diverse array of substrates, including inorganic
and organic ions3,4, and range in specificity — from
highly selective transporters that interact with a narrow
group of substrates, such as amino acid transporters in the
SLC7 family 5,6, to transporters that accept a broad range
of chemically diverse substrates such as do the OATs
in the SLCO family 7,8. Even within a family, various
transporters may differ in their degree of specificity. For
example, in the SLC22 family, urate anion exchanger 1

(URAT1; also known as SLC22A12) is selective for uric
acid, whereas OAT1 accepts a wide range of organic
anions, including various antibiotics, antiviral drugs and
endogenous molecules9.
SLC transporters are predominantly facilitative or
secondary-active; that is, they rely either on an electrochemical gradient to facilitate the movement of
substrates across membranes, or on ion gradients generated by ATP-dependent pumps to transport substrates
against the concentration gradient. Tertiary-active transporters, such as OAT1, rely on gradients generated by
secondary-active transporters and can also transport
their substrates against a concentration gradient.
Much remains unknown about SLC transporters —
partly because many cell lines that have undergone multiple passages lose transporter expression and activity
— although the field is advancing rapidly. Within the
past 10 years, 9 new SLC families have been identified
and nearly 100 human SLC genes have been recognized. Crystal structures and molecular models of SLC
transporters are increasingly available10,11. Slc-knockout
mice have also enabled the study of the contributions of
specific transporters, although often deciphering these
contributions is complex (BOX 2). The SLC families of
transporters have recently been reviewed4.
Members of the SLC transporter families are important
in human physiology. For example, amino acids, which
are needed for protein synthesis, are absorbed and
reabsorbed by transporters of the SLC1, SLC3, SLC6,
SLC7, SLC25 and SLC36 families, many members of
which are expressed in the intestine and kidney. In the
intestine, amino acids are absorbed from the lumen into
the body; in the kidney, amino acids that are filtered out
of the bloodstream by the glomerulus are reabsorbed in
the proximal tubule by many of the same transporters that
are involved in intestinal absorption12. Members of the
SLC2, SLC5 and SLC50 families are required for intestinal
absorption and renal reabsorption of glucose and for glucose uptake into neurons, erythrocytes, hepatocytes and
other cell types13,14. Metals often serve as essential cofactors for important enzymes, but toxicities may occur when
they are present at excess concentrations. Zinc transporters of the SLC30 and SLC39 families and iron transporters
of the SLC11 and SLC40 families regulate zinc and iron
levels in the body, respectively. Similarly, water-soluble
vitamins are essential for various processes but require
transporters for cellular uptake; for instance, SLC19 family members transport folate and thiamine, SLC46 family
members transport folate and the SLC52 family transports riboflavin. In the brain, neurotransmitters released
into the synapse are taken back into presynaptic neurons
through SLC1 and SLC6 transporters. Interestingly, the
roles of many transporters in human physiology have
been discovered through studies of Mendelian disease
(TABLE 1; see Supplementary information S1 (table)).

SLC transporters in disease
Mendelian diseases associated with SLC transporters.
Given the key physiological roles of SLC transporters, it is
not surprising that defects in a single transporter can result
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Box 2 | Study of transporter–transporter interplay using knockout mice
Although in vitro studies provide a wealth of information on individual transporters,
in vivo, transporters often work together. Therefore, the use of knockout mice has been
particularly helpful in deciphering the relative contribution of a specific transporter
when multiple transporters with overlapping substrate specificities are expressed in
the same tissue. Overall, knockout mice studies are useful to determine the relationship
between transporters with similar transport functions. However, knockout of a
transporter may be compensated by the availability or upregulation of other
transporters that can transport the same substrate.
For example, creatinine is a substrate of the kidney transporters organic anion
transporter 1 (OAT1; encoded by SLC22A6) and OAT3 (encoded by SLC22A8).
Both Slc22a6−/− mice and Slc22a8−/− mice showed lower net renal creatinine secretion
compared with wild-type mice, but plasma creatinine levels were significantly higher in
Slc22a8−/− compared with wild-type mice, whereas this effect was not as pronounced
in Slc22a6−/− mice163. This result suggests that OAT3 may be more important than
OAT1 in the renal secretion of creatinine in mice.
However, in some cases, certain transporters may be upregulated in knockout
mice, sometimes obscuring the relative contribution of a transporter to a particular
phenotype. For example, organic cation transporter 3 (OCT3; encoded by SLC22A3)
and serotonin transporter (SERT; encoded by SLC6A4) transport serotonin with low and
high affinity, respectively164. In SERT-knockout mice (Slc6a4−/−), Slc22a3 transcript levels
increase in the hippocampus but not in other regions of the brain165. This upregulation
of Slc22a3 in the absence of Slc6a4 plays an important part in the uptake of serotonin,
and may obscure the full effect of SERT in vivo.
Not surprisingly, if the substrate of a transporter is an important endogenous
compound, rare loss‑of‑function mutations in the gene encoding the transporter will
often lead to a disease phenotype (see Supplementary information S2 (table)). In mice,
thiamine is absorbed in the intestine through the thiamine transporters THTR1
(encoded by SLC19A2) and THTR2 (encoded by SLC19A3). In Slc19a2−/− mice, Slc19a3
transcript levels increase in the intestine, although there is no upregulation of
Slc19a2 in Slc19a3−/− mice166. Interestingly, these knockout mouse studies reflect
characteristics of human disease in patients with thiamine-responsive megaloblastic
anaemia. These patients are homozygous for mutations in SLC19A2 and show normal
thiamine plasma levels due to sufficient thiamine absorption in the intestine by THTR2.
However, patients with a mutation in SLC19A3 suffer from thiamine metabolism
dysfunction syndrome 2 (Online Mendelian Inheritance in Man (OMIM) database
#607483; see Databases), and exhibit thiamine deficiency and related CNS
symptoms167,168. Although it is not known whether the expression levels of the thiamine
transporter paralogues are altered in these diseases, this is an illustrative example
of how loss of function of one of two transporters that are thought to have the same
function can have very different effects.

in a serious disease. Mutations in 20% of the genes encoding
known SLC transporters in humans have been associated with Mendelian disease (see the Online Mendelian
Inheritance in Man (OMIM) database in Databases), and
it is likely that mutations in more SLC transporter genes
will be found to be causal for some of the remaining half
of Mendelian diseases with no known cause. The defective
transporters or transporter deficiencies that cause these
diseases result in a wide range of symptoms that affect
almost all organ systems; although some of these diseases
are considered to be benign, others cause serious illness
and death. TABLE 1 and Supplementary information S1, S2
(tables) summarize the information that is known about
each transporter and the Mendelian disease associated
with its dysfunction or lack of expression. FIGURE 1 illustrates the potential mechanisms through which mutations
in genes encoding SLC transporters can result in reduced
function. FIGURE 2 shows the transporters that are implicated in Mendelian diseases, organized by the general
class of substrates they transport.

Common diseases associated with SLC transporters. SLC
transporter gene polymorphisms that are associated with
common disease have generally been identified through
the genotyping of candidate genes, or from GWASs (see
Catalog of Published Genome-wide Association Studies
in Further information). Examples of transporter genes
for which polymorphisms have been associated with
human traits or disease include the following: SLC22A4
and SLC22A5, which are associated with inflammatory
bowel disease15–17; SLC2A9, SLC22A11 and SLC22A12,
which are associated with gout and uric acid levels18–20;
SLCO1B1 and SLCO1B3, which are associated with
high bilirubin levels21–24; and SLC24A5 and SLC45A2,
which are associated with skin colour 25,26. Many of the
polymorphisms implicated in human disease are nonsynonymous — that is, they cause amino acid substitutions in the encoded transporter that reduce transporter
function or expression levels. For example, non-synony
mous variants of the uric acid transporters encoded by
SLC2A9, SLC22A11 and SLC22A12 show reduced uric acid
transport in vitro. A reduced-function variant will reabsorb
less uric acid from the urine. As a result, hypouricaemia
can occur, thus reducing the risk of gout.
Polymorphisms in the genes encoding the hepatic
transporters OATP1B1 (SLCO1B1) and OATP1B3
(SLCO1B3) provide a second example. These transporters are responsible for the uptake of conjugated
bilirubin — the product of haem metabolic catabolism
— into hepatocytes. From there, it is excreted into the
bile. Common polymorphisms in the genes of transporters that are involved in the hepatic bilirubin elimination
pathway may lead to hyperbilirubinaemia and jaundice.
Moreover, the complete loss of SLCO1B1 and SLCO1B3
results in a rare disease known as Rotor syndrome27
(BOX 3). This example, wherein a common reducedfunction gene polymorphism is associated with a less serious phenotype, whereas a rare, more severe defect in the
same gene causes a Mendelian disease, is not uncommon
in human genetic studies.
There have been several transporters discovered
through GWASs that were not previously known to be
important in human disease, including the following
examples: SLC30A8, which encodes a pancreatic β-cellspecific zinc transporter, a genetic polymorphism of
which has been associated with diabetes28,29; SLC14A1,
which encodes a urea transporter, variants of which have
been associated with bladder cancer 30; SLC4A7, which
encodes a bicarbonate transporter, for which certain poly
morphisms have been associated with abnormal blood
pressure31,32 or with breast cancer33; and the gene encoding
a nucleoside-sugar transporter that also transports thiamine, SLC35F3, some polymorphisms of which have
been associated with increased blood pressure and predicted to cause disturbances in cardiac and autonomic
function34.
Variants in SLC30A8 have been associated with type 2
diabetes in several GWASs and across different ethnic
groups. A non-synonymous variant in SLC30A8, with
a high allele frequency (>25% in Caucasians and Asians),
p.Arg325Trp (rs13266634), was identified through
a GWAS28. This risk allele, p.Arg325Trp, is associated
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Table 1 | SLC transporters that are implicated in Mendelian diseases and other disorders*
Substrate
category

No. of
transporters
implicated
in Mendelian
disease (total 84)

No. of
Mendelian
diseases
(total 100)

SLC transporters
with mutations
leading to
Mendelian
disease (total 84)

Examples of
substrates

Comments‡

Amino acids

7

6

SLC3A1, SLC6A19,
SLC6A20, SLC7A9,
SLC25A12,
SLC25A38,
SLC36A2

Glutamate,
glycine, proline,
cysteine,
tryptophan,
aspartate

• SLC7A5 (REFS 140,141) and SLC7A11
are potential new targets for cancer
• Sulfasalazine, originally developed for
arthritis, inhibits SLC7A11 (REF. 172)

Urea cycle

5

6

SLC2A9, SLC7A7,
SLC22A12,
SLC25A13,
SLC25A15

Lysine, ornithine,
citrulline,
aspartate, uric acid,
glutamate

Glucose

6

9

SLC2A1, SLC2A2,
SLC2A10, SLC5A1,
SLC5A2, SLC37A4

Glucose, galactose,
mannose, fructose,
glucose‑6‑
phosphate

Nucleotide
sugars

4

4

SLC35A1,
SLC35A2,
SLC35C1,
SLC35D1

UDP-glucuronic
acid, GDP-fucose,
UDP-galactose,
UDP‑N‑acetyl
galactosamine

Metals

6

6

SLC11A2, SLC30A2, Zinc, iron, ferrous
SLC30A10,
ion, manganese
SLC39A4,
SLC39A13,
SLC40A1

Vitamins

7

9

SLC19A2,
SLC19A3,
SLC25A19,
SLC46A1,
SLC52A1,
SLC52A2, SLC52A3

Folate, thiamine,
thiamine
pyrophosphate,
riboflavin

Neurotransmitter

7

7

SLC1A3, SLC5A7,
SLC6A2, SLC6A3,
SLC6A5, SLC17A8,
SLC25A22

Noradrenaline,
serotonin,
dopamine,
glutamate, glycine,
aspartate, choline

• Tiagabine, a drug used for the treatment of
epilepsy, inhibits SLC6A1 (REF. 174)
• SLC18A2 inhibitors such as amphetamine,
reserpine and tetrabenazine are used for
the treatment of movement disorders and
hypertension
• Novel SLC18A2 inhibitors in clinical
development include NBI‑98854, which is in
Phase III trials for dyskinesia (NCT02274558),
and lobeline, which is in Phase II trials for ADHD
(NCT00664703)
• An SLC6A9 inhibitor, bitopertin, was in Phase III
clinical trials for the treatment of schizophrenia
but failed to meet the primary end point
(NCT01235559, NCT01235585, NCT01192906
and NCT01192880)
• Clinical trials are ongoing for bitopertin for the
treatment of OCD (NCT01674361)175
• Another SLC6A9 inhibitor, PF‑04958242, is in
Phase I trials (NCT02341482)
• Inhibition of SLC17As after nervous system injury
may mitigate further damage176
• SLC18A2 imaging agent 18F‑DTBZ is in Phase II
trials as a biomarker for Parkinson disease
(NCT01283347); it is also in observational studies
to measure β-cell mass (NCT02236754 and
NCT00771576)
• An imaging probe targeting SLC18A3 is
under investigation to detect early Alzheimer
disease152
• Glutamate transporters may be drug targets for
various neuropsychiatric and neurodegenerative
diseases177
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Table 1 (cont.) | SLC transporters that are implicated in Mendelian diseases and other disorders*
Substrate
category

No. of
transporters
implicated
in Mendelian
disease (total 84)

No. of
Mendelian
diseases
(total 100)

SLC transporters
with mutations
leading to
Mendelian
disease (total 84)

Examples of
substrates

Inorganic ions

19

27

SLC4A1, SLC4A4,
SLC4A11,
SLC9A3R1,
SLC9A6, SLC12A1,
SLC12A3,
SLC12A6,
SLC20A2,
SLC24A1,
SLC24A5,
SLC25A3,
SLC26A3,
SLC26A2,
SLC26A5,
SLC26A8,
SLC34A1,
SLC34A2, SLC34A3

Chloride,
• Diuretic drugs such as bumetanide and
bicarbonate,
furosemide inhibit various SLC12 transporters,
hydroxide, sodium,
including SLC12A1, SLC12A2, SLC12A3,
calcium, potassium,
SLC12A4 and SLC12A5
phosphate, sulfate, • Transporters in the SLC9A family have been
oxalate, rubidium
studied as drug targets in cancer139,173
• SLC9A1 is activated during
oncogene-dependent transformation and
may represent a potential new target for the
treatment of cancer139,173

Thyroid

3

4

SLC5A5, SLC16A2,
SLC26A4

Iodide,
iodothyronines

Organic anions 2

1

SLCO1B1,
SLCO1B3

Oestradiol
glucuronide,
oestrone sulfate,
bilirubin

• Probenecid, an SLC22A6 inhibitor, can be
co‑administered to prevent nephrotoxicity
associated with drug (for example, cidofovir)
overdose

Miscellaneous

21

SLC6A8, SLC10A2,
SLC13A5,
SLC16A1,
SLC16A12,
SLC17A5,
SLC22A5,
SLC25A1,
SLC25A4,
SLC25A20,
SLC27A4,
SLC29A3,
SLC33A1,
SLC42A1,
SLC45A2,
SLC49A1,
SLC49A2,
SLCO2A1

Carnitine,
creatinine,
taurocholic,
ADP–ATP,
acetyl-CoA,
melanin,
prostaglandin,
sialic acid,
pyruvate, lactate,
long-chain fatty
acids, adenosine,
citrate, haem,
ammonia

• Clodronate, an inhibitor of SLC25A4,
SLC25A5 and SLC25A6, is used for the
treatment of osteoporosis178

18

Comments‡

F‑DTBZ, 18F-9‑fluoroprolyl-(+)-dihydrotetrabenazine; ADHD, attention-deficit hyperactivity disorder; GDP, guanidine diphosphate; OCD, obsessive-compulsive
disorder; SLC, solute carrier; UDP, uridine diphosphate. *For detailed information about each of these SLC transporters and the Mendelian diseases, see Supplementary
information S1, S2 (tables). ‡All the clinical trials mentioned in this table are registered on ClinicalTrials.gov (see Databases).
18

with reduced susceptibility to type 2 diabetes and higher
zinc transport activity. It was subsequently demonstrated
in Slc30a8‑knockout mice that the transporter plays a
part in transporting zinc ions from the cytoplasm into
insulin granules35, and further studies suggested that zinc
may have an important role as an endogenous regulator of insulin homeostasis36,37. Furthermore, although
Slc30a8‑deficient mice exhibit phenotypic variability, they
generally show lower blood insulin levels and increased
insulin clearance38. Interestingly, a recent paper by Flannick
et al.39 demonstrated that carriers of loss‑of‑function
and rare missense variants in SLC30A8 were at reduced
risk for type 2 diabetes. The researchers performed
sequencing or genotyping on more than 150,000 individuals and demonstrated that loss‑of‑function
missense SLC30A8 variants that led to truncation of the

transporter protein actually protected individuals from
type 2 diabetes. Overall, these human genetic studies
suggest that SLC30A8 could be a potential target for the
treatment and/or prevention of type 2 diabetes.

Strategies for targeting SLC transporters
Inhibition of transporter function. Most current drugs
— as well as novel drugs in clinical trials — that modulate SLC transporters do so by inhibiting transporter
activity, and examples of these are described in more
detail in the subsequent sections. For diseases in which
decreased transporter activity leads to a potentially beneficial effect, high-throughput screening (HTS) of large
compound libraries using cell lines that overexpress
the transporter of interest can be used to discover lead
inhibitor molecules40,41.
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Figure 1 | Overview of the different types of mutations in SLC transporter genes, and their effects.
Transcription occurs in the nucleus and translation in the ribosomes. Normal, folded proteins translocate in vesicles
Nature Reviews | Drug Discovery
across the endoplasmic reticulum and to the Golgi apparatus. Once through the Golgi, proteins are trafficked to
the cell surface membrane, where they fuse to the plasma membrane to form the functional solute carrier (SLC)
transporter. Mutations in the gene encoding the transporter may result in poor transporter function owing to several
different factors. First, improper translation could result in a misfolded protein. In this case, the misfolded protein
may be ubiquitylated and degraded in the proteasome. Second, the SLC transporter protein may not be trafficked to
the cell surface membrane. Finally, mutations in the gene could cause an intracellular accumulation of the misfolded
protein, resulting in abnormal intracellular signalling and initiation of the unfolded protein response to degrade the
protein. Drugs can affect any of the various steps to alter transport function. For example, riluzole increases the RNA
transcript levels of excitatory amino acid carrier 1 (EAAC1), ultimately resulting in an enhanced uptake of glutamate
from the neuronal synapse.

Many SLC transporters may function in both influx
and efflux of their substrates, and the net direction of flux
across a cellular membrane is dependent on the substrate
gradient (or, in the case of secondary or tertiary transporters, the gradient of the co- or counter-transported
ions). Because of their simplicity, influx assays are frequently used in screening studies. In particular, cells that
are grown on solid support are typically used to screen
for inhibitors that prevent the uptake or influx of a fluorescent substrate probe42–44. Even for transporters that
require a co- or counter-transported ion, the assays may
be set up in the influx mode for convenience. For example,

a high concentration of extracellular sodium may be
used to drive the influx of a fluorescent probe, or the
cells may be pre-loaded with a counterion to drive fluo
rescent probe influx. For transporters that are primarily
efflux transporters, such as the ABC transporters bile salt
export pump (BSEP; also known as ABCB11), canalicular
multidrug resistance protein (cMRP; also known as
ABCC2) and breast cancer resistance protein (BCRP;
also known as ABCG2), a vesicular-transport assay is
frequently used. Instead of adherent cells, membrane
fractions that contain inside-out vesicles are prepared
from cells that overexpress the efflux transporter 45–48.
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Z’ assay sensitivity factor
A measure of statistical effect
size that takes into account the
mean and standard deviation
of both the positive and the
negative controls.

Pharmacophore modelling
Use of a geometric description
of the chemical functions of
a target protein to generate
and use 3D structural
information to search for
novel active compounds.
Models may be generated
by either ligand-based or
structure-based methods.

Quantitative structure–
activity relationship
(QSAR) modelling
Use of a regression model to
find relationships between
the physical or chemical
properties and the biological
activity of a molecule, based
on the assumption that these
features are related.

Docking
A computational method used
to predict the orientation of
molecules during interactions
with a target protein.

Homology models
Molecular models of a target
protein created from its amino
acid sequence and the 3D
structure of a homologous
protein.

A fluorescent or radiolabelled substrate probe that
can be quantitatively measured is added to each well
in the presence and absence of each test compound
to determine the transporter-inhibiting activity of the
compounds. The concentration of the substrate probe
and uptake time that produce the best Z’ assay sensitivity
factor is selected; a Z’ > 0.8 is ideal for HTS, although
Z’ > 0.5 is also acceptable49. Such methods have been
used to screen thousands of compounds in HTS campaigns. However, HTS also suffers from limitations. One
commonly observed issue relates to assay interference,
whereby aggregation of a test compound that causes
protein sequestration or nonspecific inhibition results
in a false-positive hit; this problem affects 1.7–1.9% of
total compounds in compound libraries50–52. Another
problem arises from the interference of fluorescent test
compounds or contaminating particulate matter with
the measurement of the fluorescent substrate probe.
A ‘pre-read’ control measurement after the addition of
the test compound but before substrate addition can prevent this problem. Use of an orange or red fluorophore
as the substrate also helps to avoid this interference, as
fluorescence and spurious light emissions from test compounds have been found to be more likely to occur at
shorter wavelengths50.
The structure of identified potential inhibitors can
be modified to produce more-potent or more-selective
molecules. Pharmacophore modelling and quantitative
structure–activity relationship (QSAR) modelling may be used
to engineer improved compounds with more-desirable
properties53,54. Novel inhibitors for many transporters
have been identified through these methods, including inhibitors of apical sodium-dependent bile acid
transporter (ASBT; also known as SLC10A2)55,56, excitatory amino acid transporter 3 (EAAT3; also known
as SLC1A1)57, dopamine transporter (DAT; also known as
SLC6A3), serotonin transporter (SERT; also known
as SLC6A4), noradrenaline transporter (NET; also
known as SLC6A2)58–60 and vesicular glutamate transporter 2 (VGLUT2; also known as SLC17A6)61. For
example, the O‑spiroketal C‑arylglucoside scaffold
— which forms the basis of tofogliflozin (Apleway/
Deberza; Chugai Pharmaceutical/Sanofi/Kowa, a selective sodium–glucose cotransporter 2 (SGLT2; also
known as SLC5A2) inhibitor recently approved in Japan
for the treatment of diabetes — was found by pharmacophore modelling of SGLT2 inhibitors and a search of
the Cambridge Structural Database62 (see Databases).
Homology modelling and docking have been widely
used to identify and optimize lead compounds. As the
crystal structures of SLC transporters from various species become increasingly available3,63, homology models
of human orthologues are being constructed that can
be used in molecular docking studies to design moreselective transporter inhibitors. These methods have
been successfully used to identify binding sites, to
accurately predict the inhibitory actions of alreadyprescribed drugs on SLC transporters and to identify
potent transporter inhibitors for treating diseases5,11,64.
For example, high-throughput docking of the glutamatebinding site on the Pyrococcus horikoshii glutamate

transporter homologue was used to identify a potent
inhibitor of EAAT2 (also known as SLC1A2)65, and the
crystal structure of the same concentrative nucleoside
transporter from Vibrio cholerae was used to identify a
selective anticancer drug 66,67. The crystal structures of
bacterial homologues of neurotransmitter transporters
bound to antidepressant drugs were recently elucidated,
enabling researchers to identify the amino acid residues
that comprise the binding sites of these transporters68–70.
Such information may be implemented to design and
synthesize more-potent serotonin- and/or noradrenalinereuptake inhibitors71.
Enhancement of transporter function. For most
Mendelian diseases in which causal variants of the genes
encoding SLCs result in loss of transporter function,
compounds that enhance the function of the affected
transporter are needed; these compounds are also of
interest in the treatment of common diseases. To our
knowledge, no current drugs were originally developed
specifically to activate SLC transporters. Riluzole, a drug
used to treat amyotrophic lateral sclerosis, inhibits glutamate release, thereby preventing glutamate-induced
activation of sodium channels on postsynaptic neurons72, reducing excitotoxicity. However, riluzole was
subsequently found to enhance the transport activity of
EAAT1 (also known as SLC1A3), which takes up extracellular glutamate from the synapse and thus reduces
glutamate levels in the synaptic cleft 73,74. Another study
showed that riluzole stimulates glutamate uptake by
increasing excitatory amino acid carrier 1 (EAAC1; also
known as SLC1A1) levels in astroglial cells75, although
the exact mechanism for this effect is not completely
understood.
There is interest in identifying additional targets to
increase glutamate clearance. Similar to EAAT1, EAAT2
(the principal glutamate transporter in astrocytes)
reduces glutamate levels in the synaptic cleft, thereby
attenuating excitotoxicity. Some examples of neurodegenerative diseases that could benefit from upregulated
EAAT2 function include Alzheimer disease, amyotrophic lateral sclerosis and Parkinson disease — all
of which have been associated with decreased EAAT2
protein expression levels76,77 — as well as epilepsy,
stroke and neurotrauma78. Therefore, developing a drug
that enhances EAAT2 activity represents a promising
approach in central nervous system (CNS) drug development 79. Two approaches are currently being used to
identify enhancers of EAAT2. First, an HTS assay that
used a reporter gene containing the SLC1A2 promoter
upstream of the luciferase gene found that several currently prescribed drugs, such as ceftriaxone, increased
luciferase transcript levels80. Second, an astrocyte-based
enzyme-linked immunosorbent assay has been developed to screen large compound libraries for molecules
that can induce translation of silenced SLC1A2 transcripts, as the expression of EAAT2 protein is highly regulated at the translational level by extracellular factors81.
These and other screening technologies — for example,
high-throughput fluorescence assays — could be used
to identify compounds that enhance SLC transporter
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Figure 2 | SLC transporters implicated in Mendelian diseases, grouped by
substrate type. A total of 84 solute carrier (SLC) transporters have been implicated
in Mendelian diseases. The number in each segment indicates
the number
ofDiscovery
Nature Reviews
| Drug
transporters. See Supplementary information S1 (table) for more information.

activity. The development of drugs that enhance the
activity of cystic fibrosis transmembrane conductance
regulator (CFTR; also known as ABCC7), the ABC
transporter that is defective in cystic fibrosis, could provide a model for the identification of small molecules
that may rescue mutated SLC transporters. Smallmolecule therapies for modulating CFTR fall into two
categories: potentiators and correctors. Various assays
have been developed to identify potentiators and correctors, such as ivacaftor, the first US-regulator-approved
drug to target a specific CFTR mutant, CFTR‑G551D.
Ivacaftor acts as a potentiator; it increases the activity
of CFTR‑G551D that is already present on the plasma
membrane, by increasing the probability of the open
state of the CFTR channel82. By contrast, correctors
enhance the trafficking of mutant proteins such as the
most common cystic-fibrosis-causing mutant protein,
CFTR‑F508del, to the plasma membrane. Early clinical
results suggest that the combination of a corrector and
a potentiator results in enhanced efficacy in the treatment of individuals with cystic fibrosis who harbour the
CFTR‑F508del mutation83.
Circumventing transporters. Another potential therapeutic strategy for treating rare diseases caused by
mutant SLC transporters is to develop substrates that
circumvent transporters. SLC transporter gene mutations that lead to Mendelian disease often also lead to
subnormal levels of an essential nutrient, such as thiamine or carnitine, in specific tissues. Therapies that
circumvent the use of the mutant transporter could
be developed. For example, creation of a hydrolysable
hydrophobic derivative of an essential nutrient that is
normally hydrophilic may result in enhanced permea
bility of the nutrient. Thus, the hydrophobic derivative
would enter the cell (without the aid of a transporter)
where it would undergo hydrolysis and release the nutrient, thus enhancing the availability of the nutrient in the
cell to treat, for instance, thiamine deficiency 84.

However, a potential problem in the development of
diffusible analogues that circumvent transporters may be
the low cellular availability of the analogue. For example,
many transporters are secondary-active and therefore
concentrate their substrates intracellularly, whereas
diffusible analogues may not accumulate to the same
extent. Furthermore, hydrophobic diffusible analogues
may be substrates for efflux pumps of the ABC transporter families, such as MDR1, that preferentially handle
hydrophobic substrates, and may therefore exhibit poor
cellular availability. Finally, diffusible analogues may distribute widely into body tissues rather than selectively
targeting the tissues of greatest need (for example, in the
case of carnitine deficiency, the liver).
Gene therapy. Gene therapy, in principle, may be a
strategy for the treatment of diseases caused by mutant
transporter proteins. Several animal studies have provided proof of concept for this strategy. For example,
Yiu et al.85 infused an adenoviral vector containing the
gene encoding human glucose‑6‑phosphate transporter
(SLC37A4) into Slc37a4‑deficient mice (which recapitulate the human glycogen-storage disease type Ib that is
attributable to mutations in SLC37A4). The gene therapy
restored SLC37A4 expression in various tissues (including the liver), normalized serum glucose and serum
lipid profiles, and reduced glycogen deposition in the
liver. Although historically fraught with issues, gene
therapy may become a viable strategy for the treatment
of Mendelian disorders that involve defective membrane
transporters as more-advanced methods are applied.

SLC transporters as targets of drugs
Many SLC transporters have been identified as druggable — that is, they contribute to a disease phenotype
and can be modulated by drugs86. More information can
be found in TABLE 1 and TABLE 2. Databases87–91 such as
the Sophic Integrated Druggable Genome Database, the
DrugBank database (see Databases) and recent review
articles88,92 provide useful and detailed information
about already-approved drugs that target SLC transporters for various diseases. In this section, we provide four
examples of approved drug classes for which the primary
mechanisms of action involve inhibition of SLC transporters: diuretics, neurotransmitter-reuptake inhibitors
for neuropsychiatric indications, glucose transporter
inhibitors for diabetes and uric acid transporter inhibitors for gout. We also highlight several other examples of transporters that are being targeted by drugs in
development.
SLC12 transporters as targets of diuretic drugs. Diuretics
are important drugs used to treat hypertension and
heart failure. The discovery of the first diuretic, chloro
thiazide (which belongs to the thiazide class), in 1957,
was followed by the discoveries of the loop diuretics
bumetanide and furosemide. Subsequently, Wiley and
Cooper 93 observed that furosemide inhibits the influx
and efflux of sodium and potassium in human red
blood cells and concluded that the drug inhibits the
cotransport of sodium and potassium. In addition, using
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Box 3 | Rotor syndrome: a loss of function in two SLC transporters
Mutant solute carrier (SLC) transporters are frequently linked to rare but clinically
significant (inherited) disease phenotypes. For certain inherited diseases associated
with bilirubin metabolism or transport, the molecular basis of such defects has been
elucidated for more than a decade. For example, the efflux multidrug resistanceassociated protein 2 (MRP2; encoded by ABCC2) secretes conjugated bilirubin in
the bile duct, and complete-loss‑of‑function mutations in ABCC2 are the basis of
Dubin–Johnson syndrome169.
Interestingly, the genetic basis for another similar condition, known as Rotor
syndrome, which is also known to result in conjugated hyperbilirubinaemia, had
remained unresolved. Recently, two hepatic SLC transporters, organic anion
transporter family member 1B1 (OATP1B1; encoded by SLCO1B1) and OATP1B3
(encoded by SLCO1B3), have been implicated in Rotor syndrome170. Notably,
mutations or deletions that affect both SLCO1B1 and SLCO1B3 are required to result
in this phenotype. Moreover, the pathway of hepatic conjugated-bilirubin secretion
and reuptake was further clarified through the linkage of mutations in the genes
encoding these OATP transporters.
It is now clear that the conjugated hyperbilirubinaemia observed in Rotor syndrome
is not due to an inability to secrete conjugated bilirubin into bile through transporters
such as MRP2 that are expressed on the canalicular domain. Rather, a considerable
proportion of conjugated bilirubin seems to be actively extruded into the sinusoidal
blood through the hepatocytic MRP3 (encoded by ABCC3), another ATP-binding
cassette (ABC) transporter, whereas OATP1B1 and OATP1B3 take up conjugated
bilirubin back into hepatocytes. Interestingly, a complete absence of both OATP1B1
and OATP1B3 does not appear to result in substantial liver pathology, as Rotor
syndrome is considered a benign condition27. The fact that an absence of both these
transporters alters the clearance of conjugated bilirubin suggests that there may be
another as yet undetermined transporter (or transporters) for unconjugated bilirubin.
It should be noted that commonly occurring single nucleotide polymorphisms in
SLCO1B1 have been associated with adverse responses to substrate drugs, including
the statin class of lipid-lowering drugs171.
The genetic basis of Rotor syndrome suggests that profound loss‑of‑function
mutations in the genes encoding these transporters may be more common than
currently appreciated, and that a more worrisome phenotype among those who
carry such mutations may be severe toxicity to substrate drugs.

isolated perfused rabbit kidney tubules, Burg et al.94
described the inhibitory effect of furosemide on active
chloride transport in the thick ascending limbs of the
loop of Henle, which results in a decreased net absorption of sodium chloride and a decreased electrical potential (that is, a more positive electrical potential) in tubule
cells. Sodium–chloride cotransport was recognized in
the 1970s and has since been studied in a wide variety of
animal cells and tissues.
The role of a sodium–chloride cotransporter is to
maintain and regulate cell volumes and ion gradients;
thus, diuretics that inhibit such cotransporters in the
renal tubules decrease extracellular fluid volume and
regulate electrolyte levels in the body 95. The functional
expression of the sodium–potassium–chloride cotransporter in HEK293 kidney cells was first revealed by Xu
et al.96, who used radiolabelled rubidium as a tracer for
potassium movement and showed that cells transfected
with the sodium–potassium–chloride cotransporter had a
greater influx of 86Rb, which was inhibited by bumetanide,
a loop diuretic. Subsequently, it was established that diuretics inhibit the sodium–potassium–chloride cotransporter NKCC2 (also known as SLC12A1) to reduce
sodium reabsorption in the thick ascending limb of the
loop of Henle. The reduction in sodium reabsorption

results in increased sodium levels in the tubule fluid and a
corresponding loss of body water, thus increasing urine
production and decreasing blood volume.
Interestingly, mutations in the gene encoding NKCC2
(SLC12A1), which is expressed in the kidney, were found
to cause Bartter syndrome, an inherited hypokalaemic
alkalosis featuring hypercalciuria and severe blood
volume depletion97. Moreover, mutations in SLC12A3,
which encodes the sodium–chloride cotransporter TSC
(normally expressed in the renal distal tubule) were
found to cause Gitelman syndrome, in which patients
present with hypokalaemic alkalosis and abnormalities in electrolyte homeostasis98. In contrast to NKCC2,
which is sensitive to loop diuretics such as bumetanide
but insensitive to thiazides, TSC is sensitive to the thia
zides chlorothiazide and hydrochlorothiazide but is
insensitive to loop diuretics.
At high doses, thiazides are used to relieve systemic
and pulmonary oedema due to chronic heart failure,
and at lower doses to reduce blood pressure. One of the
major adverse effects of thiazides and loop diuretics is
hypokalaemia, which is especially dangerous in patients
with severe cardiovascular disease. Furthermore, high
doses of thiazides can also cause hyperuricaemia. One
possible explanation for this effect is that diuretics may
inhibit renal transporters such as OAT1 (SLC22A6),
OAT3 (also known as SLC22A8), sodium–phosphate
cotransporter 1 (NPT1; also known as SLC17A1) and
NPT4 (SLC17A3), which are all involved in uric acid
secretion, and thus increase serum uric acid levels99,100.
Urea transporters of the SLC14 family also play an
important role in the recycling of urea and in concentrating urine. As a result, several research groups are
screening for small-molecule inhibitors to target urea
transporters, particularly UTB (also known as SLC14A1)
and UTA (also known as SLC14A2). Such inhibitors cause
an increase in urine output due to decreased urea concentrations in the urine. Perhaps in the near future, a new
class of diuretics that inhibit UTB and UTA transporters
will be developed.

SLC6 transporters as neuropsychiatric drug targets.
Drugs for treating depression can be classified according
to their presumed targets, which may be transporters.
For example, the monoamine-reuptake inhibitors —
which include the serotonin-selective reuptake inhibitors
(SSRIs) and noradrenaline-reuptake inhibitors (NRIs) —
inhibit neurotransmitter transporters. Over the past several decades, the development of novel antidepressants
has moved from ‘discovery by chance’ to single-target
strategies, and then to multiple-target strategies.
Several transporters in the SLC6 family have important roles in the uptake of monoamines in the synapses of the CNS. These include NET (SLC6A2), DAT
(SLC6A3) and SERT (SLC6A4), which are transporters
for noradrenaline, dopamine and serotonin (also known
as 5‑hydroxytryptamine), respectively, although they
all exhibit overlapping substrate specificity. Inhibition
of these transporters by drugs reduces the clearance
of monoamine neurotransmitters from the synapse,
thus increasing their dwell time in the synaptic cleft.
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Table 2 | SLC transporters implicated in Mendelian diseases that may potentially be targets of new drugs
Substrate class

Protein
(gene)

Disease (disease
prevalence if
known)*

Current or potential drug target‡

Neurotransmitter

EAAT1
(SLC1A3)

Episodic ataxia
type 6

• Riluzole, which facilitates EAAT1, is used for ALS73
• Loss of EAAT1 has been found in patients with ALS179
• EAAT1 is upregulated in chronic brain ischaemia180
• EAAT1 inhibitors have been developed as pharmacological tools181–183

Glucose

GLUT1
(SLC2A1)

GLUT1 deficiency
syndrome; also
known as dystonia 9
or dystonia 18
(1 in 90,000 in
Australia)

• Triheptanoin has reached Phase II trials to treat GLUT1 deficiency syndrome
(NCT02036853)
• GLUT1 expression levels are correlated to 18F-FDG uptake values184,185
• A small-molecule inhibitor of GLUT1 was able to inhibit cancer cell growth in vitro
and in vivo186

Glucose

SGLT1
(SLC5A1)

Glucose–galactose
malabsorption
(300 cases to date)

• Several inhibitors of SGLT1 and/or SGLT2 have been approved to treat type 2
diabetes, including canagliflozin, dapagliflozin and empagliflozin187,188; tofogliflozin
and ipragliflozin are approved for use in Japan
• Clinical trials are ongoing or have completed for other SGLT1 and/or SGLT2
inhibitors including: GSK1614235, which is in Phase I trials (NCT01607385);
remogliflozin, in Phase II trials (NCT00495469 and NCT00376038); sotagliflozin,
in Phase III trials (NCT02384941); and ertugliflozin, in Phase III trials
(NCT01986881, NCT01999218, NCT01958671, NCT01986855, NCT02036515
and NCT02226003)

Glucose

SGLT2
(SLC5A2)

Familial renal
glucosuria
(0.16–6.3% in the
United States189)

• See entry for SGLT1

Thyroid

NIS
(SLC5A5)

Thyroid
dyshormonogenesis
(1 in 100,000
newborns)

• A PET imaging probe, [99mTc]-pertechnetate, is being studied for imaging and
radioiodine therapy by targeting NIS190,191

Neurotransmitter

NET
(SLC6A2)

Orthostatic
intolerance

• Many antidepressants, including fluoxetine, citalopram, sertraline, venlafaxine
and duloxetine target neurotransmitter-reuptake transporters including NET,
DAT and SERT

Neurotransmitter

DAT
(SLC6A3)

Infantile
parkinsonismdystonia (8 cases
to date)

• See entry for NET
• A radioligand for DAT, (1R)-2β‑carbomethoxy‑3β-(4-[123I]iodophenyl)tropane
([123I]β-CIT), could be used clinically as a nuclear imaging marker for Parkinson
disease192,193

Neurotransmitter

GLYT2
(SLC6A5)

Hyperekplexia 3
(<1 in 1,000,000)

• Inhibitors of GLYT2 may be used for the glycinergic control of pain194 or
overactive bladder195
• An SLC6A5 inhibitor, VVZ‑149, is in Phase I trials for pain (NCT01905410)

Miscellaneous

CRTR
(SLC6A8)

Cerebral creatine
deficiency syndrome
(0.3–3.5% in males)

• Creatine analogues may be used to enhance creatine levels in the brain196–198

Inorganic ions

NHE6
(SLC9A6)

Christianson
syndrome (<30 cases
to date)

• NHE6 is upregulated in tumour cells under hypoxic conditions139,173

Miscellaneous

ASBT
(SLC10A2)

Primary bile acid
malabsorption

• ASBT is a potential drug target in diabetes and in individuals with
hypertriglyceridaemia 127,199
• Drugs can be conjugated to bile acids to target ASBT to enhance drug uptake
into intestine131,200
• Several inhibitors of ASBT are in development: LUM001 is in Phase II trials
for cholestatic liver diseases (NCT02057718, NCT01904058, NCT02057692,
NCT02117713 and NCT02061540); SHP626 is in a Phase I trial for the
treatment of NASH (NCT02287779); elobixibat is in Phase II trials for chronic
idiopathic constipation (NCT01895543); and A4250 is in Phase II trials for
PBC (NCT02360852)

Inorganic ions

NKCC2
(SLC12A1)

Bartter syndrome
type I (1 in 1,000,000)

• Diuretic drugs such as bumetanide and furosemide inhibit NKCC2

Miscellaneous

MCT1
(SLC16A1)

Erythrocyte lactate
transporter defect

• MCT1 is upregulated in cancer201,202
• Inhibitors of MCT1 may be used as a target for immunosuppression or cancer201,203,204
• An MCT1 inhibitor, AZD3965, is in Phase I trials for patients with cancer
(NCT01791595)
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Table 2 (cont.) | SLC transporters implicated in Mendelian diseases that may potentially be targets of new drugs
Substrate class

Protein
(gene)

Disease (disease
prevalence if
known)*

Current or potential drug target‡

Neurotransmitter

VGLUT3
(SLC17A8)

Autosomal dominant • VGLUT inhibitors block the uptake of glutamate into vesicles and reduce
deafness type 25
excitotoxic events to prevent acute CNS injury and chronic neurodegenerative
disease61,176,205,206

Vitamins

THTR2
(SLC19A3)

Thiamine
metabolism
dysfunction
syndrome 2

• A Janus kinase 2 inhibitor, fedratinib, led to thiamine deficiency and Wernicke
encephalopathy, resulting in the withdrawal of the drug during Phase III trials;
it was later found to inhibit THTR2207

Urea cycle

URAT1
(SLC22A12)

Renal
hypouricaemia 1
(2.37% in Japan208)

• Lesinurad, a URAT1 inhibitor, is US-approved for the treatment of gout
• Clinical trials are ongoing for other URAT1 inhibitors, including RDEA3170
in Phase II trials (NCT01927198) and KUX‑1151 in Phase II trials (NCT02190786)120

Miscellaneous

CACT
(SLC25A20)

Carnitineacylcarnitine
translocase
deficiency

• Statins, fibrates and retinoic acid upregulate SLC25A20 expression209

Thyroid

PDS
(SLC26A4)

Pendred syndrome
(7.5% of congenital
deafness210)

• PDS has an important role in the distal tubule salt reabsorption and may represent a
novel target for a new diuretic211

Glucose

G6PT1,
(SLC37A4)

Glycogen-storage
disease type Ib
or Ic (1 in 100,000
(REF. 212))

• Mice with glycogen-storage disease type Ia show increased Slc37a4 mRNA levels
after a 24‑hour fast; gene therapy to restore G6PT1 function has been shown in
these mice213,214

Miscellaneous

FLVCR1
(SLC49A1)

Posterior column
ataxia with retinitis
pigmentosa
(20 cases to date)

• Inhibition of FLVCR1 results in decreased haem export in an erythroid cell line;
however, Slc49a1‑knockout mice develop iron overload in microphages215

F‑FDG, 18F‑fluoro-2‑deoxy-d-glucose; ALS, amyotrophic lateral sclerosis; ASBT, apical sodium-dependent bile acid transporter; CACT, carnitine-acylcarnitine
translocase; CNS, central nervous system; CRTR, creatine transporter; DAT, dopamine transporter; EAAT1, excitatory amino acid transporter 1; FLVCR1, feline
leukaemia virus subgroup C receptor-related protein 1; G6PT1, glucose‑6‑phosphate translocase 1; GLUT1, glucose transporter type 1; GLYT2, glycine transporter 2;
MCT1, monocarboxylate transporter 1; NASH, non‑alcoholic steatohepatitis; NET, noradrenaline transporter; NHE6, sodium–hydrogen exchanger 6; NKCC2,
sodium–potassium–chloride cotransporter 2; NIS, sodium–iodide symporter; PBC, primary biliary cirrhosis; PDS, pendrin; PET, positron emission tomography;
SERT, serotonin transporter; SGLT, sodium–glucose cotransporter; SLC, solute carrier; THTR2, thiamine transporter 2; URAT1, urate anion exchanger 1;
VGLUT3, vesicular glutamate transporter 3. *Additional information on diseases mentioned in this table can be found via the Online Mendelian Inheritance
in Man (OMIM) database (see Databases) or the US National Library of Medicine’s Genetics Home Reference or Orphanet (see Further information).
‡
All of the clinical trials mentioned in this table are registered on ClinicalTrials.gov (see Databases).
18

The resulting increased concentrations of monoamines
in the synaptic cleft enhance receptor occupancy, leading
to increased activation of ligand-gated ion channels and
modulation of G-protein-coupled receptor signalling 101.
However, the downstream mechanisms by which such
drugs ultimately exert antidepressant effects (which can
take weeks to become apparent) are not yet clear 102.
The first-generation tricyclic antidepressants (TCAs)
inhibit serotonin and noradrenaline reuptake, but also
interact with other targets in the CNS. In the 1960s,
several investigators showed that TCAs such as imipramine competitively inhibit serotonin and noradrenaline
uptake in several tissue types, including platelet-rich
plasma, brain slices and synaptosomes. TCAs were
used as the primary treatment for depression until
the US approval of the first SSRI, fluoxetine, in 1987.
Fluoxetine was found to inhibit serotonin uptake into
rat brain synaptosomes, without inhibiting noradrenaline
uptake into rat hearts103,104.
Since the discovery of fluoxetine and other SSRIs,
other classes of compounds that affect neurotransmitter reuptake have been developed. For example,

serotonin–noradrenaline reuptake inhibitors (SNRIs),
such as venlafaxine, are a newer class of antidepressants
that selectively target two transporters, NET and SERT.
The use of SSRIs and SNRIs has also expanded to other
neuropsychiatric disorders, including anorexia nervosa,
bulimia nervosa, obsessive-compulsive disorder, panic
disorders and anxiety disorders, as well as for relief of
menopausal symptoms.
Another therapeutic target for the treatment of neuro
psychiatric disorders is vesicular monoamine transporter 2
(VMAT2; also known as SLC18A2), which transports
monoamines from the cellular cytosol into synaptic
vesicles. An inhibitor of VMAT2, tetrabenazine, is currently US-approved for the treatment of hyperkinetic
disorders associated with Huntington disorder 105. Other
VMAT2 inhibitors are in clinical development, including NBI‑98854 (developed by Neurocrine Biosciences),
which is in Phase III trials for dyskinesia (ClinicalTrials.
gov identifier: NCT02274558; note that all trials cited
in this article are from this database (see Databases))
and a natural product, lobeline (developed by Yaupon
Therapeutics), which is in Phase II trials for the treatment
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of attention-deficit hyperactivity disorder in adults
(NCT00664703). VMAT2 inhibitors may also be developed for the treatment of psychostimulant abuse and
addiction106.

glucose levels and increasing urinary glucose excretion,
SGLT2 inhibitors have also been associated with weight
loss and lowering of blood pressure owing to their
osmotic diuretic effects116.

Glucose transporter inhibitors. The SGLT2 (SLC5A2)
transporter, which has a low affinity and high capacity
for glucose, plays a major part in renal glucose reabsorption, whereas the high-affinity, low-capacity SGLT1
(also known as SLC5A1) transporter has a major role in
glucose absorption in the small intestine107. By mimicking the effects of a loss‑of‑function mutation in SGLT2
(TABLE 1), SGLT2 inhibitors enhance renal glucose excretion and consequently lower plasma glucose levels.
Many companies have been developing drugs that
target SGLT1 and SGLT2 for type 2 diabetes, in which
patients exhibit hyperglycaemia owing to insulin resistance. In such programmes, compound libraries were
screened for lead compounds that inhibit glucose uptake
in cell lines that stably expressed human SGLT1 or SGLT2
(REFS 108,109). Once the lead compounds were identified, their in vivo effects were determined in murine
and other animal models to confirm that the compound
could increase urinary glucose excretion by inhibiting
renal glucose reabsorption. Importantly, oral glucose
tolerance tests in diabetic rats revealed that these animals were responsive to treatment with SGLT2 inhibitors110. Moreover, patients with type 2 diabetes who were
treated with the SGLT2 inhibitor empagliflozin showed
improved β-cell function and insulin sensitivity. Chronic
dosing with empagliflozin for 4 weeks in these patients
led to a significant decline in both glycated haemoglobin
and fasting glucose levels111.
Canagliflozin (Invokana; Mitsubishi Tanabe Pharma/
Johnson & Johnson) was the first SGLT2 inhibitor to be
approved by the US Food and Drug Administration
(FDA) in 2013, and was followed by dapagliflozin
(Farxiga/Forxiga; Bristol-Myers Squibb/AstraZeneca)
and empagliflozin (Jardiance; Boehringer Ingelheim/
Eli Lilly and Company) in 2014. All three drugs are
being prescribed as second-line therapy for patients
whose diabetes is inadequately controlled by a single
antidiabetic agent 112. Tofogliflozin and ipragliflozin
(Suglat; Astellas/Kotobuki) have both been approved
for the treatment of type 2 diabetes in Japan, and
both have active Phase IV trials ongoing (tofogliflozin:
NCT02201004 and NCT02284269; ipragliflozin:
NCT02291874 and NCT02175784). Other SGLT1 and/
or SGLT2 inhibitors are being studied in early- and latephase clinical studies either alone or in combination
with metformin (which suppresses glucose production
by the liver)113–115. These SGLT inhibitors include the
following: remogliflozin (also known as GSK189075;
developed by GlaxoSmithKline), which is in Phase II
trials (NCT00495469); GSK1614235 (GlaxoSmithKline),
in Phase I trials (NCT01607385); sotaglifozin (Lexicon
Pharmaceuticals), in Phase III trials (NCT02384941);
and ertugliflozin (Merck &Co./Pfizer), in Phase III
trials (NCT01986881, NCT01999218, NCT01958671,
NCT01986855, NCT02036515 and NCT02226003). In
addition to having notable effects on reducing plasma

Uric acid transporter inhibitors. Gout is the most common
inflammatory arthritic disease, and has been increasing in
prevalence in the United States and in other countries,
partly as a consequence of the obesity epidemic117. Gout is
caused by the accumulation of monosodium urate monohydrate crystals in the joints and soft tissue, as a result of
hyperuricaemia. Most current treatments for gout generally target the inflammation that occurs during an acute
gout attack or reduce uric acid production by inhibiting
the enzymes involved (for example, allopurinol, which
inhibits xanthine oxidase). However, many patients fail
to respond to these treatments or suffer from serious side
effects (for instance, allopurinol can cause drug hypersensitivity reactions)118.
Recent advances in the understanding of uric acid
transporters, through GWASs and other studies, have
opened the door for the development of novel compounds that target these transporters in the kidney as a
way to block reuptake of uric acid and thereby promote
elimination of uric acid in the urine. The primary uric acid
reabsorption transporters include URAT1 (SLC22A12)
and glucose transporter type 9 (GLUT9; also known as
SLC2A9), which are expressed in the proximal tubule,
although other transporters have also been identified that
transport urate or are associated with gout118,119. Although
probenecid, which has been used for decades to treat gout,
blocks uric acid reabsorption through organic anion transporters, several novel compounds are currently in development for this indication that are more selective, and most
target URAT1. Lesinurad, a URAT1 inhibitor developed
by Ardea Biosciences/AstraZeneca was recently approved
by the European Medicines Agency on the basis of results
from two trials testing the drug for the treatment of hyperuricaemia in combination with xanthine oxidase inhibitors
in patients with gout (NCT01510158 and NCT01493531).
Another URAT1 inhibitor, RDEA3170, is also being developed by Ardea Biosciences/AstraZeneca and has completed Phase II trials (NCT01927198)120. Meanwhile, Pfizer
recently licensed KUX‑1151 from Kissei Pharmaceutical;
this dual inhibitor of xanthine oxidase and of URAT1 is
currently in a Phase II trial in Japan (NCT02190786). As
URAT1 inhibitors selectively inhibit URAT1 and reduce
uric acid reabsorption in the kidney, their effects mimic
those observed in patients with URAT1 mutations that lead
to renal hypouricaemia type 1.
Glycine transporter inhibitors. In the CNS, glycine has
important roles in neuronal inhibition and excitation.
It functions as an inhibitory neurotransmitter by activating ionotropic glycine receptors, enabling an influx of
chloride ions and hyperpolarization of the postsynaptic
membrane. Glycine also binds to excitatory N‑methyld‑aspartate (NMDA) receptors to enable receptor activation by glutamate121. The glycine transporters GLYT1
(also known as SLC6A9) and GLYT2 (also known as
SLC6A5) on neurons, astrocytes and glial cells regulate
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levels of extracellular glycine in the brain, and thereby
regulate NMDA receptor activity. According to the glutamate hypothesis of schizophrenia, symptoms of the
disease are caused by deficient glutamatergic (NMDA)
signalling, and therefore GLYT1 inhibitors have been
developed to inhibit glycine reuptake and increase levels
of glycine at NMDA receptors to enhance NMDA signalling in this disorder.
Bitopertin (also known as RO4917838), a highly
selective and potent GLYT1 inhibitor developed by
Roche, is furthest along in development 122. However,
several Phase III studies of bitopertin in schizophrenia
(NCT01235559, NCT01235585, NCT01192906 and
NCT01192880) failed to reach their primary end point,
leaving bitopertin with an uncertain future. Nevertheless,
there is a Phase II trial currently ongoing using bitopertin
with SSRIs in patients with obsessive-compulsive disorder
(NCT01674361). The GLYT1 inhibitor PF‑04958242 is
still listed in Pfizer’s Phase I pipeline and has completed
multiple Phase I studies (NCT01159483, NCT02228395,
NCT02332798, NCT01511510 and NCT01518894), but
the development of several other investigational GLYT1
inhibitors for the treatment of schizophrenia, including
compounds from Pfizer, GlaxoSmithKline, Amgen,
Merck, Johnson & Johnson and Sanofi, appears to have
stopped (see Evaluate Pharma article 21 Jan 2014 in
Further information). However, there is evidence to suggest that GLYT2 inhibitors reduce pain in animal models
of chronic pain, and thus there is probably work ongoing
in the development of partial GLYT2 inhibitors that can
be used for pain relief without serious side effects123. One
such compound, VVZ‑149, a dual inhibitor of GLYT2
and 5‑hydroxytryptamine receptor 2A, is under development by Vivozon and completed a Phase I study in 2014
(NCT01905410).
Bile acid transporter inhibitors. Bile acids are the principal
components of bile and their primary function is to
solubilize fat and other dietary nutrients, although they
can also function as signalling molecules124. Bile acids
are synthesized in the liver from cholesterol through the
action of the rate-limiting enzyme cytochrome P450
7A1. Bile acid uptake and efflux transporters in the
intestine and liver play key roles in the highly efficient
enterohepatic recycling pathway, through which more
than 90% of the total pool of bile acids are reabsorbed
from the intestine and transported back to the liver via
the portal circulation125. ASBT (SLC10A2) mediates the
reabsorption of bile acids from the lumen of the intestine126. Inhibition of bile acid reabsorption in the intestine
would result in a loss of bile acids and increased conversion of cholesterol to bile acid in the liver, thereby
lowering circulating cholesterol levels and potentially
ameliorating or preventing the progression of cardiovascular disease. Thus, not surprisingly, inhibiting ASBT
has received a substantial amount of attention as a potential therapeutic strategy for lowering cholesterol127, and
several pharmaceutical companies are developing potent
and specific inhibitors of ASBT as therapeutic agents
with this aim126. Interestingly, the rare genetic disorder
primary bile acid malabsorption syndrome is caused by

loss‑of‑function mutations in ASBT128. Individuals with
this disorder suffer from chronic diarrhoea and fat-soluble
vitamin deficiency, and importantly, exhibit lower
plasma cholesterol levels128.
Given the potency and efficacy of statins, as well as
newer agents such as ezetimibe (Zetia; Merck & Co.) that
target cholesterol absorption in the intestine, the extent of
clinical benefit of ASBT inhibition (relative to the potential side effects) remains to be clarified. However, there
now appears to be more-compelling evidence for targeting
ASBT for cholestatic liver diseases such as primary biliary
cirrhosis, for which treatment options have been limited. LUM001, an ASBT inhibitor developed by Lumena
Pharmaceuticals (now Shire), is currently in Phase II clinical trials for the treatment of cholestatic liver diseases,
including primary biliary cirrhosis129 (NCT02057718,
NCT01904058, NCT02057692, NCT02117713 and
NCT02061540). Another ASBT inhibitor developed by
Shire, SHP626, is currently recruiting participants for
Phase I trials for the treatment of nonalcoholic steatohepatitis in overweight adults (NCT02287779). Albiero
Pharma is also currently developing ASBT inhibitors of its
own — elobixibat has just completed a Phase III trial for
chronic idiopathic constipation (NCT01895543). A4250
(Albireo) received orphan drug designation from the FDA
in 2012 for the treatment of progressive familial intra
hepatic cholestasis and primary biliary cirrhosis, and is
currently in Phase II trials in patients with primary biliary
cirrhosis (NCT02360852). It is likely that there are other
pharmaceutical companies pursuing ASBT as a therapeutic target for cholestatic liver disease, as many have done
so for reducing cholesterol.
Because bile acids promote the secretion of intestinal
incretin peptides (such as glucagon-like peptide 1) that
in turn stimulate pancreatic insulin secretion, inhibition
of ASBT may also be a viable strategy for the treatment of
type 2 diabetes130. GlaxoSmithKline recently completed
two Phase II studies using a combination of GSK2330672
plus metformin to treat diabetes (NCT02202161 and
NCT01929863). Furthermore, targeting ASBT has also
been proposed as a prodrug strategy for compounds
that have poor oral bioavailability, as coupling an active
drug molecule with a bile acid moiety would increase the
absorption of the drug in the intestine131.
Nutrient transporter inhibitors. Tumour cells have an
increased demand for nutrients owing to their rapid proliferation and growth. However, many amino acids and
carbohydrates are too polar to diffuse across cell membranes, and thus require transporter proteins for cellular
uptake. In theory, tumour growth can be controlled by
starving the cells of the metabolic precursors needed for
sustained growth. Such an approach can be used to selectively kill tumour cells, which are generally locked into a
state of rapid growth by oncogenes and are therefore more
sensitive to starvation than are normal cells. Moreover,
nutrient transporters have been found to be overexpressed
in a wide variety of cancers132. To date, no anticancer drug
has been developed to specifically inhibit a nutrient transporter with the explicit goal of controlling cell growth.
However, inhibition of key nutrient transporters, such as
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the glucose transporters of the SLC2 and SLC5 families,
amino acid transporters of the SLC7 family and lactate
transporters of the SLC16 family, may be a reasonable
approach for discovering new anticancer drugs133.
As glucose is the primary energy source in most cells,
it is unsurprising that glucose transporters such as GLUT1
(SLC2A1) are often overexpressed in tumour cells in a variety of tissues134,135. Indeed, [18F]-fluoro‑2‑deoxy‑d‑glucose
(18F-FDG) positron emission tomography (PET) imaging,
which is used to detect and stage tumours, is dependent
on the rate of cellular glucose uptake. However, increased
glycolysis is associated with an increase in the generation of
lactate, which cells need to remove to maintain cellular pH
levels. There is often also an upregulation of lactate transporters (such as monocarboxylate transporter 1 (MCT1;
also known as SLC16A1))136,137, or transporters important
in pH regulation (such as sodium–hydrogen exchanger 1
(NHE1; also known as SLC9A1))138,139 in cancer cells.
Various research groups have identified MCT1 inhibitors. For example, the MCT1 inhibitor AZD3965, developed by Cancer Research UK, is currently in Phase I
clinical trials for patients with advanced solid tumours
or lymphoma (NCT01791595). Similarly, amino acid
transporters (such as L-type amino acid transporter 1
(LAT1; also known as SLC7A5)140,141, ASC amino acid
transporter 2 (ASCT2; also known as SLC1A5)142 and
cystine–glutamate exchange transporter (XCT; also
known as SLC7A11)143) are also overexpressed in a
variety of tumours and may be potential anticancer targets.
Sulfasalazine, which was initially developed as an antiinflammatory drug to treat rheumatoid arthritis, was
subsequently found to inhibit XCT144 and has anticancer effects in various cancer xenograft models143. As
our understanding of the importance of transporters in
tumour cell metabolism increases, it is highly likely that
the development of anticancer drugs that target different
nutrient transporters will continue.

SLC-targeting imaging agents
PET imaging probes, some of which exploit SLC transporters for uptake into cells, are widely used in the clinic,
particularly in diagnosing disease145. 18F-FDG, a widely
used PET imaging probe, is transported into cells via
GLUT1, which is upregulated in many cancers. GLUT1
upregulation, which enables higher 18F-FDG uptake in
tumour cells, is frequently associated with poor cancer
prognosis146,147.
In addition to cancer diagnosis, several PET imaging
probes that inhibit SLC transporters are in clinical development for guiding drug treatment in other disorders.
For example, PET radioligands that inhibit SERT, DAT
or NET can provide information on the occupancy of
these neurotransmitter transporters by various drugs
in patients with depression, to understand the mechanisms of nonresponses to drug therapies148–150. Another
interesting use of PET imaging probes is the detection
of monoaminergic degeneration in Parkinson disease. 18F-9‑fluoroprolyl-(+)-dihydrotetrabenzazine
(18F-DTBZ) is a radioligand that targets VMAT2, which
transports monoamine neurotransmitters from the neuronal cytosol into synaptic vesicles. As VMAT2 density

is correlated with the integrity of dopaminergic neurons
in the brain, measuring VMAT2 occupancy using
18
F-DTBZ may enable early diagnosis and monitoring
of monoaminergic degeneration in Parkinson disease151.
This imaging agent is under investigation as an in vivo
biomarker for Parkinson disease; it has completed one
Phase II trial (NCT01283347) and is currently in two
more (NCT02059733 and NCT02039024). As VMAT2
can be a marker of islet β‑cells, observational studies using the same agent are ongoing to measure β‑cell
mass in healthy individuals and in patients with diabetes
(NCT02236754 and NCT00771576). Similarly, an imaging probe for the vesicular acetylcholine transporter
VACHT is currently under investigation to assist in the
detection of early Alzheimer disease152, which typically
leads to deficits in acetylcholine transmission.
Drug–drug interactions can also be studied using
PET imaging by administering a radiolabelled drug that
is known to be a transporter substrate in conjunction
with an unlabelled drug 153. In this way, an interaction
between a substrate and an inhibitor of a transporter
may be observed in multiple organs simultaneously.
For example, [11C]‑metformin could be useful as PET
probe to study drug–drug interactions that are mediated
by multidrug and toxin extrusion protein 1 (MATE1;
also known as SLC47A1) in the liver and kidney 154.

Conclusions and future directions
SLC transporters represent a plethora of new therapeutic
targets for rare diseases, and may be particularly amenable
to targeting with small molecules. Importantly, many SLC
transporters are expressed on the cell surface and are therefore targetable by both small molecules and therapeutic
antibodies. Furthermore, there are many examples of SLC
transporters that are targets of already approved drugs,
as well as of drugs in development.
However, several challenges remain for targeting
SLC transporters. Although 92% of known drug-target
structures have been deposited in the Protein Data Bank
(see Databases), most SLC transporters have not been
crystallized, thus limiting computer-aided drug discovery efforts3. Moreover, many SLC transporters remain
orphans, with unknown function and unknown substrates. Finally, SLC transporters located in intracellular
compartments may not be as amenable to drug targeting. For example, to our knowledge, the SLC25 family of
mitochondrial transporters, some of which are associated with Mendelian disease, have not yet been targeted.
Despite these obstacles, the potential for discovering
inhibitors of transporters or modulators of transporter
activity is enormous. The development of small molecules
that can target specific variants of the ABC transporter
CFTR suggests that efforts to target mutant SLC transporters may be possible. In some rare diseases, hydrophobic
nutrient derivatives that can circumvent dysfunctional
membrane transporters could be used to deliver necessary
nutrients to cells. A comprehensive understanding of the
mechanisms responsible for rare and common diseases
— including the function of the transporters and the pathways in which they act — will be crucial for recognizing
other proteins that may be therapeutically targeted.
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